Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of EV71 Vaccine in Infants
NCT03278132Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jul 2017
- Primary completion
- Sep 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enterovirus 71 vaccine (vero cell), inactivated in HIV-associated central nervous system involvement (HAND) (3 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Seroconversion rate of EV71 neutralizing antibody 30 days after the two doses vaccination. Started Jul 2017; status: completed.
02
Drugs
enterovirus 71 vaccine (vero cell), inactivated
03
Conditions
HIV-associated central nervous system involvement (HAND)
Beyond the preview
Go deeper on NCT03278132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278132.